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Sir,
As research advances, a growing body of evidence shows that the
individual response to any drug, i.e. effectiveness and toxicity, may
be influenced by genetic polymorphisms. In the case of anticancer
chemotherapeutic agents, characterised by a low therapeutic index,
pharmacogenomic studies could stratify patients for expected
response and adverse effects, potentially allowing more rational
prescriptions.
Among various drugs, irinotecan has been extensively studied.
Actually it is a prodrug affected by two main dose-limiting
toxicities: neutropoenia and delayed diarrhoea. The recent work by
Rouits et al evaluates the role of the polymorphisms of two
enzymes involved in irinotecan metabolism: UGT1A1, responsible
for glucuronisation and disposal of its active metabolite SN-38;
carboxylesterase-2 (CES2), responsible for SN-38 formation.
CYP3A4 activity, responsible for irinotecan transformation into
the inactive compounds APC and NPC, has been indirectly
estimated by urinary 6b-hydroxycortisol/cortisol ratio, and can
be influenced by many ambiental factors (Rouits et al, 2008).
As authors say, UGT1A1 variants affect only haematological
toxicity. An earlier, larger trial had similar results, but was
statistically significant only for the first cycle and did not correlate
with necessity of dose reduction (Toffoli et al, 2006). Carboxylester-
ase-2 variants are not significantly correlated with any parameter,
whereas urinary 6b-hydroxycortisol/cortisol ratio seemed as a
global predictor of toxicity including diarrhoea, but it could simply
reflect hepatic dysfunction and therefore needs further evaluation.
These results are somewhat disappointing. Chemotherapy-
induced neutropoenia can be easily managed with recombinant
myeloid growth factors if necessary, whereas diarrhoea cannot
be reliably predicted and is sometimes severe. The complex
pharmacology of irinotecan can actually be influenced by many
factors, both genetic and nongenetic. In particular its action on the
intestinal mucosa is strongly influenced by local environmental
factors, especially intestinal microflora.
Actually SN-38 glucuronide, excreted in faeces, can be processed
by bacterial b-glucuronidase and converted back to SN-38, which
can damage intestinal epithelial cells and thus induce delayed
diarrhoea. This hypothesis have been suggested by Takasuna et al
who showed that intestinal damage due to irinotecan administra-
tion is more pronounced in gut segments with high b-glucuro-
nidase activity (Takasuna et al, 1996).
A subsequent study specifically aimed at investigating the role of
intestinal microflora in irinotecan-induced diarrhoea compared
holoxenic and germ-free mice. Irinotecan lethal dose is more than
twice higher in the second group, which also exhibited signifi-
cantly less diarrhoea. Intestinal damage as shown by histological
examination reflected bacterial distribution along the gut, in
particular it was negligible in germ-free animals treated at
60mgkg
1d
1 for 4 days, the lethal dose for holoxenic controls
(Brandi et al, 2006).
The poor predictive value for diarrhoea of the genetic loci
studied by Rouits et al is therefore not surprising. In humans,
intestinal microflora composition is quite stable along life and
host-specific, representing a sort of adjunctive fingerprint.
Consequently, b-glucuronidase activity characteristic of some
bacterial strains only, can be quite changeable among various
subjects. Both factors (genetic polymorphisms and intestinal
microflora) can influence irinotecan intestinal toxicity: this
constitutes the rationale for the necessity of evaluating also
intestinal microflora and b-glucuronidase role in future studies
investigating its interindividual variability.
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